(VIANEWS) – The Market ended the session with MDXHEALTH (MDXH.BR) jumping 14.78% to €0.26 on Tuesday, after three sequential sessions in a row of gains. BEL 20 jumped 1.75% to €3,540.94, following the last session’s downward trend on what was an all-around up trend trading session today.
MDXHEALTH’s last close was €0.23, 71.25% below its 52-week high of €0.80.
About MDXHEALTH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Earnings Per Share
As for profitability, MDXHEALTH has a trailing twelve months EPS of €-0.23.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -171.13%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MDXHEALTH’s stock is considered to be oversold (<=20).
Volatility
MDXHEALTH’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.90%, a negative 1.27%, and a positive 2.65%.
MDXHEALTH’s highest amplitude of average volatility was 2.53% (last week), 2.94% (last month), and 2.65% (last quarter).
More news about MDXHEALTH (MDXH.BR).
